血管因 VEGF) n抗vEGF适体 Eyetech生产的 pegaptanib Macugen) ■玻璃体内注射 FDA已批准 Macugen上市 b At week 54. 70% of patients(206/294)receiving MACUGEN 0. 3 mg lost <15 letters vs 55% of 26% patients(164/296)receiving usual care!(primar 36%38% Predominantly classic ■ Minimally classic Study EOP1003: 73% with MACUGEN vs 60% with usual care H Occult Study EOP1004: 67% with MACUGEN vs 53% with usual care At week 102, 59% of patients(78/133)receiving MACUGEN 0.3 mg lost <15 letters vs 45% of 0151ze patients(48/107) receiving usual care 57%4%1c4dkx Study EOP 1003: 57% with MACUGEN vs 56% with usual care ■4-12 disc areas Study EOP1004. 61% with MACUGEN vs 34% with usual care MACUGEN is indicated for the treatment of neovascular age-related macular degeneration (AMD)
抗血管内皮生长因子（VEGF） 抗VEGF 适体 Eyetech 生产的pegaptanib(Macugen) 玻璃体内注射 FDA已批准Macugen上市
血管 138(VEGF) n重组人抗vEGF单克隆 抗体片段 rhu Fab v2 由 Genetech生产 FUTURE 正在进行Ⅲ期临床试 Genentech introduces Genentech is bringing the first anti-VEGF years of innovation 验 therapy for metastatic and new hope colorectal cancer: to more patients: Humanize Antt∈Gl Biotechnology to Ophthalmol
抗血管内皮生长因子（VEGF） 重组人抗VEGF 单克隆 抗体片段 rhu Fab V2 由Genetech 生产 正在进行 Ⅲ期临床试 验